Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Song JS, Chang CC, Wu CH, Dinh TK, Jan JJ, Huang KW, Chou MC, Shiue TY, Yeh KC, Ke YY, Yeh TK, Ta YN, Lee CJ, Huang JK, Sung YC, Shia KS, Chen Y. Song JS, et al. Among authors: chen y. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2015433118. doi: 10.1073/pnas.2015433118. Proc Natl Acad Sci U S A. 2021. PMID: 33753481 Free PMC article.
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, Duda DG, Chen Y. Sung YC, et al. Among authors: chen lh, chen y. Theranostics. 2018 Jan 1;8(4):894-905. doi: 10.7150/thno.21168. eCollection 2018. Theranostics. 2018. PMID: 29463989 Free PMC article.
165,340 results
You have reached the last available page of results. Please see the User Guide for more information.